RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

Data from Phase 3 MORPHO trial selected for press briefing and to be presented as oral session during the 2023 European Hematology Association (EHA) Hybrid Congress Exploratory results demonstrated ...

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...

- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML - - Findings from the Phase 3 ...

Impact of Postoperative Radiotherapy on the Prognosis of Early-Stage (pT1-2N0M0) Oral Tongue Squamous Cell Carcinoma Adults with FLT3-ITD AML in first remission underwent HCT and were randomly ...

TORONTO, June 16, 2025 /CNW/ - Daiichi Sankyo's (TSE: 4568) VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline induction and ...

Acute myeloid leukemia (AML) is a cancer of the bone marrow and the blood that progresses rapidly without treatment. The National Cancer Institute estimates 20,800 new cases of AML will be diagnosed ...

The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated ...

The positive preliminary SENTI-202 clinical data was presented on April 27 in a Clinical Trials Oral Minisymposium at the American Association for Cancer Research (AACR) Annual Meeting 2025 in an ...